Current Overview on Hypercoagulability in COVID-19

Link to article at PubMed

Am J Cardiovasc Drugs. 2020 Aug 4. doi: 10.1007/s40256-020-00431-z. Online ahead of print.

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought many unique pathologies, such as coagulopathy, prompting a desperate need for effective management. COVID-19-associated coagulopathy (CAC) can cause various thromboembolic complications, especially in critically ill patients. The pathogenesis is likely due to endothelial injury, immobilization, and an increase in circulating prothrombotic factors. Data on treatment are limited, although prophylactic anticoagulation is advised in all hospitalized patients. Herein, we have comprehensively reviewed the current literature available on CAC and highlight the pathogenesis, clinical features, and management of CAC.

PMID:32748336 | DOI:10.1007/s40256-020-00431-z

Leave a Reply

Your email address will not be published.